

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-	plication of:	)
	<b>,</b> —	) Art Unit: <b>1646</b>
Serial N	o. 09/753,139	)
		) Examiner: Not Yet Assigned
Filed:	<b>December 29, 2000</b>	)
		)
For:	Design and Use of Advanced Zinc	)
	<b>Chelating Peptides to Regulate Matrix</b>	)
	Metalloproteinases	)

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

As this Information Disclosure Statement is being filed after the issuance of an office action on the merits, pursuant to 37 C.F.R. §1.97(c)(2), the fee of \$180, as set forth in §1.17(p), is enclosed.

05/01/2002 SDENBOB1 00000021 09753139

01 FC:126

180.00 OP

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on April 19, 2002.

Theodore M. Green-Reg. No. 41,801

ATLLIB02 77401.1

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Musta M Da

Theodore M. Green Reg. No. 41,801

KILPATRICK STOCKTON LLP 1100 Peachtree Street, Suite 2800 Atlanta, Georgia 30309-4530, (404) 815-6500

Our Docket: 11301-0200 (44039-227522)

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 CME 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pap

Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet of 5

-	Cor	nplete if Kn wn		3
	Application Number	09/753,139	7	7
	Filing Date	December 29, 2000	帚	0
	First Named Inventor	Quirk	30	භ
	Group Art Unit	1646	0	20
	Examiner Name	Not Yet Assigned	- <u>S</u>	02
	Attorney Docket Number	11301-0200 (44039-	227532	
-				

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	U.S. Patent Number	Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	6,191,255	B1	Seiki et al.	02-20-2001	
	2	6,166,084		Bloor	12-26-2000	
	3	6,140,068		Livant	10-31-2000	
	4	6,093,398		Khaw et al.	07-25-2000	
	5	6,080,575		Heidtmann et al.	06-27-2000	
	6	6,043,087		Bini et al.	03-28-2000	
	7	6,037,137		Komoriya et al.	03-14-2000	
	8	6,025,150		Livant	02-15-2000	
	9	6,022,948		Goldberg	02-08-2000	
	10	6,020,181		Bini	02-01-2000	
	11	5,935,796		Fosang	08-10-1999	
	12	5,922,322		Bini	07-13-1999	
	13	5,834,212		Okada et al.	11-10-1998	
•	14	5,830,468		Bini	11-03-1998	
	15	5,820,874		Mahoney et al.	10-13-1998	
	16	5,804,213		Rolf	09-08-1998	
	17	5,714,342		Komoriya et al.	02-03-1998	
	18	5,605,809		Komoriya et al.	02-25-1997	
	19	5,595,885		Stetler-Stevenson et al.	01-21-1997	
	20	5,585,356		Liotta et al.	12-17-1996	
	21	5,516,891		Siwruk et al.	05-14-1996	
	22	5,484,726		Basset et al.	01-16-1996	
	23	5,389,092		Guillemet et al.	02-14-1995	
	24	5,372,809		Liotta et al.	12-13-1994	
	25	5,280,106		Liotta et al.	01-18-1994	
	26	5,270,447		Liotta et al.	12-14-1993	
	27	5,236,844		Basset et al.	08-17-1993	
	28	5,196,196		Scott et al.	03-23-1993	
	29	5,169,754		Siiman et al.	12-08-1992	
	30	5,147,339		Sundström	09-15-1992	
	31	5,112,608		Scott et al.	05-12-1992	
	32	5,059,425		Tsilibary et al.	10-22-1991	<u> </u>
	33	4,904,469		Petereit et al.	02-27-1990	
	34	4,876,332		Tsilibary et al.	10-24-1989	
	35	4,613,502		Turková	09-23-1986	

			·
1	1		
l <b>_</b> .	1	1	
Examiner	1	Date	
1	1	Date	
Signature	1	Considered	
Q.g	_	Considered	

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 995 to persons are required to respond to a collection of information unless it contains a valid OME control number

Complet if Known

Substitute for Form 1449/A/PTO

Examiner

Signature

# INFORMATION LISCH STATEMENT BY APPL

(use as many sheets as necessary

Sheet 2 of 5

Cor	nplet if Known	$\Omega$	
Application Number	09/753,139	<del></del>	3
Filing Date	December 29, 2000	m	A
First Named Invent r	Quirk	=	
Group Art Unit	1646	755	ယ
Examiner Name	Not Yet Assigned	7	2
Attorney Docket Number	11301-0200 (44039-2	27522	00
			4

		FC	REIGN PATENT DOCUMENT	<b>'S</b>	ĕ	
Examiner Initials	Cite No.1	Foreign Patent Document Kind Code <sup>5</sup> Office <sup>3</sup> Number <sup>4</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	36	EP 0 398 621 A2	Shionogi Seiyaku Kabushiki	11-22-1990		
			Kaisha			
	37	EP 0 462 182 B1	United States of America	12-27-1991	_	
	38	10287700 A	Fuji Yakuhin Kogyo KK	10-27-1998		
	39	09087299 A	Fuji Yakuhin Kogyo KK	03-31-1997		
	40	08217800 A	Fuji Yakuhin Kogyo KK	08-27-1996		
	41	08201392 A	Fuji Yakuhin Kogyo KK	08-09-1996		
	42	07159402 A	Fuji Yakuhin Kogyo KK	06-23-1995		
	43	06300757 A	Fuji Yakuhin Kogyo KK	10-28-1994		
	44	06213888 A	Fuji Yakuhin Kogyo KK	08-05-1994		
	45	05034353 A	Fuji Yakuhin Kogyo KK	02-09-1993		П
	46	10313896 A	Yamanouchi Pharmaceut Co Ltd.	12-02-1998		
	47	JP 05-244985 A2	Fuji Yakuhin Kogyo KK	09-24-1993		Т
	48	JP 04-183397 A2	Fuji Yakuhin Kogyo KK	06-30-1992		
	49	63210665 A	Fuji Yakuhin Kogyo KK	09-01-1988		Т
	50	11318449 A	Fuji Chem Ind LTD	03-09-1999		Г
	51	11083858 A	Oriental Yeast Co Ltd	03-26-1999		
	52	WO99/65519	The General Hospital Corporation	12-23-1999		
	53	WO99/05261	The New York Blood Center, Inc.	02-04-1999		
	54	WO98/42864	Board of Super Visors of Louisiana State University and Agricultural and mechanical College	10-01-1998		
	55	WO00/27625	Weyerhaeuser Company	05-18-2000		
•	56	WO98/40475	Abbott Laboratories	09-17-1998		
	57	WO98/04287	Center for Clinical & Basic Research	02-05-1998		
	58	WO98/29560	Fuji Yakuhin Kogyo Kabushiki Kaisha	07-09-1998		
	59	WO97/25437	Nederlandse Organisatie Voor Toegepastnatuurwetenschappeluk Onderzoek Tno	07-17-1997		
<del></del>	60	WO97/04080	Fuji Yakuhin Kogyo Kabushiki Kaisha	02-06-1997		
	61	WO97/00449	Aberdeen University	01-03-1997		
<u>~</u>	62	WO92/13096	Fuji Yakuhin kogyo Kabushiki Kaisha	08-06-1992		
-	63	WO92/11021	Curative Technologies, Inc.	07-09-1992		

Date

Considered

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ersons are required to respond to a collection of information unless it contains a valid OMB pantrol number Under the Paperwork Reduction Act of 1995, no.

Substitute for Form 1449/A/PTO

## INFORMATION BUSCL STATEMENT BY AF

(use as many sheets as necessary

Sheet 3 of 5

Complete if Known				
Applicati n Numb r	09/753,139	0	MA A	П
Filing Date	December 29, 2000	9	AY	
First Named Inv ntor	Quirk	TE		J
Group Art Unit	1646	36	ധ	П
Examiner Name	Not Yet Assigned	5	2	
Attorney Docket Number	11301-0200 (44039	-22352	235	11

64	WO91/12333	Kanebo, Ltd.	08-22-1991	<del></del>	
65	WO90/11287	Untied States of America	10-04-1990		
66	WO90/10228	United States of America	09-07-1990		
67	WO01/10437 A1	Saint Louis University	08-08-2000		
68	WO01/04157 A2	University of Southern California	01-18-2001	_	
69	WO00/75163 A1	Human Genome Sciences, Inc.	12-14-2000		
70	WO00/63700	The New York Blood Center,	10-26-2000		
		Inc.			
71	WO00/18805	Kyowa Hakko Kogyo Co., Ltd.	04-06-2000		
72	WO00/02904	Tschesche	01-20-2000		
73	WO/13874	Fox Chase Cancer Center	08-20-1992		
75	DE 4000-797-A	Textile & Haberdash	01-12-1990		
76	GB 2 147 206 A	Ceskoslovenska Akademie Ved	05-09-1995		
77	JP409249700A	United States of America	09-22-1997	-	

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	,
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	l T
Initials	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	'
	78	publisher, city and/or country where published  HURST et al. "Development and Characterization of a New Polyclonal Antibody Specifically Against Tissue Inhibitor of	┢
	,,,	Tions of et al. Development and origination of a Now 1 divisional Antibody operation, Against 110000 minutes of	ļ
		Metalloproteinases 4 in Human Breast Cancer" Biochem Biophys Res Commun, 2001 Feb 16, 166-171 281(1), PMID	
		11178975.	
	79	BRASSART et al. "Conformational Dependence of Collagenase (Matrix Metalloproteinase-1) Up-Regulation by Elastin	┢
	/9	BRASSART et al. Comornational Dependence of Collagenase (Matrix Metalloproteinase-1) op-regulation by Elastin	
		Peptides in Cultured Fibroblasts", J Biol Chem, 2000 Nov 17, PMID 11084020.	
	80	STRACKE et al. "Biochemical Characterization of the Catalytic Domain of Human Matrix Metalloproteinase 19. Evidence of a	
	]	Role as a Potent Basement Membrane Degrading Enzyme", J Biol Chem, 2000 May 19; 14809-16, 275 (20), PMID 10809722.	ŀ
		Note as a Potent basement wembrane begrauing Enzyme, 3 biol Chem, 2000 May 13, 14003-10, 213 (20), 1 Milb 10003/22.	
	81	OLSON et al. "Characterization of the Monomeric and Dimeric Forms of Latent and Active Matrix Metalloproteinase-9.	Г
			1
•		Differential Rates for Activation by Stromelysin 1", J Biol Chem, 2000 Jan 28, 2661-8, 275(4), PMID 10644727	
	82	FUJISE et al. "Prognostic Impact of Cathepsin B and Matrix Metalloproteinase-9 in Pulmonary Adenocarcinomas by	-
	"-	7 COLOR State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact of Guaropoint B and Malax Moderney Color State 1 Togricous Impact Impa	ļ
		Immunohistochemical Study, Lung Cancer, 2000 Jan, 19-26, 27 (1), PMID 10672780.	}
	83	JONES et al. "Expression of MMP-2 and MMP-9, Their Inhibitors, and the Activator MT1-MMP in Primary Breast Carcinomas",	-
	03	JONES et al. Expression of MMP-2 and MMP-9, Their Inhibitors, and the Activator MT 1-MMP in Primary Breast Cardinomas,	1
		J Pathol, 1999 Oct, 161-8, 189(2), PMID 10547569.	
	84	AMBROSE et al. "Detection System for Reaction-Rate Analysis in a Low-Volume Proteinase-Inhibition Assay", Anal Biochem,	
	İ	1998 Oct 15, 150-7, 263(2), PMID 9799526.	
		1990 Oct 19, 190-1, 209(2), FINID 9199920.	

Examiner	Date	
Signature	Considered	

PTO/SERIBB (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF GOMMERCE
to a collection of information unless it contains a valid OMB control number Under the Paperwork Seduction Act of persons are require

Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

		(use as many sneets as necessary		
Sheet	1	of 5		

red to respond to a collection of infor	mation unless it contains a valid	NNR COURSE URBIN	per
Con	nplete if Known	M M	
Application Number	09/753,139		
Filing Date	December 29, 2000		
First Named Inv ntor	Quirk		
Group Art Unit	1646	- Š	
Examiner Name	Not Yet Assigned	2/2	71
Attorney Docket Number	11301-0200 (44039-	227522)	

	85	HOYHTYA et al. "Monoclonal Antibodies to Type IV Collagenase Recognize a Protein with Limited Sequence Homology to
		Interstitial Collagenase and Stromelysin", FEBS Lett, 1988 Jun 6, 109-13, 233(1), PMID 2838321.
	86	NWOMEH et al. "Dynamics of the Matrix Metalloproteinases MMP-1 and MMP-8 in Acute Open Human Dermal Wounds",
		Wound Repair Regen, 1998 Mar-Apr, 127-34, 6(2), PMID 9776855.
	87	NIELSEN et al. "Expression of Matrix Metalloprotease-9 in Vascular Pericytes in Human Breast Cancer", Lab Invest, 1997
		Oct, 345-55, 77(4), PMID 9354769.
	88	KODATE et al. "Expression of Matrix Metalloproteinase (Gelatinase) in T1 Adenocarcinoma of the Lung", Pathol Int, 1997 Jul,
		461-9, 47(7), PMID 97378788.
	89	ITOH et al. "Flow Injection Analysis for Measurement of Activity of Matrix Metalloproteinase-7 (MMP-7), J Pharm Biomed
		Anal, 1997 Jun, 1417-26, 15(9-10), PMID 9226571.
•	90	VERHEIJEN et al. "Modified Proenzymes as Artificial Substrates for Proteolytic Enzymes: Colorimetric Assay of Bacterial
		Collagenase and Matrix Metalloproteinase Activity Using Modified Pro-Urokinase", Biochem J, 1997 May 1, 603-9, 323
		(Pt 3)(3), PMID 9169591.
	91	SANG et al. "Activation of Human Progelatinase A by Collagenase and Matrilysin: Activation of Procollagenase by Matrilysin",
		J Protein Chem, 1996 Apr, 243-53, 15(3), PMID 8804571.
	92	NAGASE, et al. "Human Matrix Metalloproteinase Specificity Studies Using Collagen Sequence-Based Synthetic Peptides",
		Biopolymers, 1996, 399-416, 40(4), PMID 8765610.
	93	MCGEEHAN et al. "Characterization of the Peptide Substrate Specificities of Interstitial Collagenase and 92kDa Gelatinase.
		Implications for Substrate Optimization", J Biol Chem, 1994 Dec 30, 32814-20, 269(52), PMID 7806505.
,	94	BICKETT et al. "A High Throughput Fluorogenic Substrate for Stromelysin (MMP-3), Ann NY Acad Sci, 1994 Sep 6, 351-5,
		732, PMID 7978805.
<u> </u>	95	NAGASE et al. "Design and Characterization of a Fluorogenic Substrate Selectively Hydrolyzed by Stromelysin 1 (Matrix
		Metalloproteinase-3), J Biol Chem, 1994 Aug 19, 20952-7, 269(33), PMID 8063713.
	96	OKAZAKI et al. "Gene Expression of MMPs and TIMPs in the Process of Hepatic Fibrosis" Nippon Rinsho, 1993 Feb, 428-34,
		51(2), PMID 8464157.
	97	NIEDZWIECKI et al. "Substrate Specificity of the Human Matrix Metalloproteinase Stromelysin and the Development of
		Continuous Fluorometric Assays", Biochemistry, 1992 Dec 22, 12618-23, 31(50), PMID 1472498.

		<u> </u>		
Examiner			Date	
Signature			Considered	

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 PMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF SOMMERCE

no persons are required to respond to a collection of information unless it contains a valid OMB Control number.

Under the Paperwork Seduction Act of Substitute for Form 1449/A/PTO

# **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 5 of 5

Cor	nplet if Known	2	N/	Ī
Application Number	09/753,139	Ž	₹	_
Filing Dat	December 29, 2000	113	0	_
First Named Invent r	Quirk		co	
Group Art Unit	1646	8	20	<
Examiner Name	Not Yet Assigned	0	02	П
Attorney Docket Number	11301-0200 (44039	-22552	2)	

	98	HARRISON et al. "Mechanic Studies on the Human Matrix Metalloproteinase Stromelysin", Biochemistry, 1992 Nov 10,
		10757-62, 31(44), PMID 1420192.
	99	ZUCKER et al. "Immunoassay of Type IV Collagenase/Gelatinase (MMP-2) in Human Plasma", J Immunol Methods, 1992 Apr
		8, 189-98, 148(1-2), PMID 1373424.
	100	CLARK et al. "Polyclonal Antibodies Against Human Fibroblast Collagenase and the Design of an Enzyme-Linked
		Immunosorbent Assay to Measure TIMP-Collagenase Complex", Matrix, 1992 April, 108-15, 12(2), PMID 1318493.
	101	KNIGHT et al. "A Novel Coumarin-Labelled Peptide for Sensitive Continuous Assays of the Matrix Metalloproteinases", FEBS
		Lett, 1992 Jan 27, 263-6, 296(3), PMID 1537400.
	102	ANGELTON et al. "Flourogenic Peptide Substrates Optimized for Five Human Matrix Metalloproteinases", Matrix Suppl, 1992,
		89-90, 1, PMID 1480101.
•	103	STACK et al. "Application of N-Carboxyalkyl Peptides to the Inhibition and Affinity Purification of the Porcine Matrix
		Metalloproteinases Collagenase, Gelatinase, and Stromelysin", Arch biochem Biophsys, 1992 Sep, 393, 297(2), PMID
		1654808.
	104	NETZEL-ARNETT et al. "Continuously Recording Fluorescent Assays Optimized for Five Human Matrix Metalloproteinases",
		Anal Biochem, 1991 May 15, 86-92, 195(1).
<u>-</u> .	105	CLARK et al. "Polyclonal and Monoclonal Antibodies Against Human Tissue Inhibitor of Metalloproteinases (TIMP) and the
		Design of an Enzyme-Linked Immunosorbent Assay to Measure TIMP", Matrix, 1991 Apr 76-85, 11(2), PMID 1649376.
	106	BROPHY et al. "Tissue Inhibitor of Metalloproteases (TIMP) is Matrix Associated in Aortic Tissue: Report of a
		Radioimmunoassay", Biochem Biophys Res Commun, 1990 Mar 30, 898-903, 167(3), PMID 2322285.
. •	107	TEAHAN et al. "Substrate Specificity of Human Fibroblast Stromelysin. Hydrolysis of Substance P and its Analogues",
•		Biochemistry, 1989 Oct 17, 8497-501, 28(21), PMID 2481496.
	108	HARRISON et al. "A Semicontinuous, High-Performance Liquid Chromatography-Based Assay for Stromelysin", Anal
		Biochem, 1989 Jul, 110-3, 180 (1), PMID 2479283.
	109	STETLER-STEVENSON et al. "The Activation of Human Type IV Collagenase Proenzyme. Sequence Identification of the
		Major Conversion Product Following Organomercurial Activation", J Biol Chem, 1989 Jan 25, 264(3), 1353-6, PMID 2536363.

Examiner	Date	
Signature	Considered	